MicroPort<sup>®</sup> Attends Exposition on China Indigenous Brand

Shanghai, China – From May 10 to May 12, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended the First Exposition on China Indigenous Brand and displayed its Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"), Evolution® Medial-Pivot Knee System, Rega™ Family Implantable Pacemakers, and etc to the attendees. The three-day event attracted nearly 64,000 attendees from home and abroad.
 
China has made May 10 the "China Brand Day" since 2017, showing its determination to cultivate more well-known domestic brands. And the "China Brand Day" activities got under way in China this May. Famous brands of scientific innovation not only increase a city's awareness but also drive the city's economic development. In the First Exposition on China Indigenous Brand, there is a special area dedicated to Shanghai scientific innovation in the Shanghai Pavilion, showcasing industry leading brands in the fields of medicine, energy, material, artificial intelligence, and etc.
 
MicroPort® displayed its achievements in interventional cardiology, orthopedics, and cardiac rhythm management. MicroPort® now is a premier medical solution provider covering 10 major medical disciplines including interventional radiology, electrophysiology, diabetes and endocrine management, surgical management, and others. In particular, its new-generation drug-eluting stent Firehawk® is the world's first and only target-eluting stent ("TES"). It adopts TES Technology platform, and its coating area is only 20% of the stent surface. Firehawk®'s drug is released over 90 days and its polymer is fully absorbed in nine months. Its average metal coverage rate is 14.0-16.1%. Firehawk® is the world's lowest drug dosage stent, with only 1/3 dosage versus similar products while achieving the same efficacy. Its EVOLUTION™ Knee System offers comfortable and stable solutions to patients. Up to date, nearly 600,000 Medial Pivot knees have been implanted globally. The Knee has published a study evaluating long-term clinical and radiographic outcomes of the Medial-Pivot Knee System. The results demonstrate excellent clinical outcomes for both satisfaction (95%) and survivorship (98.8%) at 17 years with patients noting a great sense of stability and comfort during regular activities. Rega™ Family Implantable Pacemakers are domestically made devices with world-class quality. It features small size and long life span. Specifically, they are the smallest pacemakers available in market with only eight cubic centimeters in volume, and they have service life of 10 to 12 years. The devices break the monopoly of imported pacemakers and help promote the development of cardiac rhythm management market in China.
 
Through years of growth and innovation in the past 20 years, MicroPort® has over 260 products currently approved for use in over 5,000 hospitals worldwide, MicroPort® is contributing to a better world through its life-saving medical therapies and quality-improving care devices being used in patients every 12 seconds. MicroPort® has over 3,000 patents, and was granted several national science and technology achievements awards and provincial-level honors. In the future, MicroPort® will continue to carry out the branding ideology of "the Patient Always Comes First" to offer cost-effective medical solutions to save or reshape lives or improve the quality of life for patients in China and worldwide.